Neuren Pharmaceuticals (ASX: NEU) today announced details on the status of its lead compounds, Glypromate® and NNZ-2566. Following is a summary of the current status of the trials. Neuren will provide further updates as the trials progress.
Neuren Pharmaceuticals (ASX: NEU) today announced details on the status of its lead compounds, Glypromate® and NNZ-2566. Following is a summary of the current status of the trials. Neuren will provide further updates as the trials progress.
